Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
This study has been completed.
Study NCT00661713
Information provided by Novartis
First Received on April 16, 2008.
Last Updated on October 24, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
